Navigation Links
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Date:11/26/2013

and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Various statements in this release concerning BioLineRx's future expectations, including specifically those related to the development and commercialization of BL-7040, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technologi
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
2. BioLineRx Reports Third Quarter 2013 Financial Results
3. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
4. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
7. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
10. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
11. BioLineRx to Present at 15th International Celiac Disease Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Pete Rose, baseball,s all-time hits leader, is the new ... Myoflex, Ducere Pharma has announced. "Pete,s a Hall ... have him on board with Myoflex," said Ducere Pharma Chief ... player who is known across all generations. The passion and ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Five Star Healthcare™, a division of Crump Insurance Services, ... largest insurance wholesaler, today announced it has added a ... The program, offered through an A.M. Best A XI ... needs of dialysis providers.  Operations of any size are ...
... CINCINNATI, May 12, 2011 Kendle (Nasdaq: KNDL ... announced it is ranked a "top CRO to work with" ... the only CRO to be ranked consistently among the top ... the annual investigative site surveys conducted by the leading clinical ...
Cached Medicine Technology:Exclusive Coverage for Kidney Dialysis Centers Offered by Five Star Healthcare 2Kendle Rated a "Top CRO to Work With" for Fifth Consecutive Year 2Kendle Rated a "Top CRO to Work With" for Fifth Consecutive Year 3Kendle Rated a "Top CRO to Work With" for Fifth Consecutive Year 4Kendle Rated a "Top CRO to Work With" for Fifth Consecutive Year 5
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... Colorado (PRWEB) January 22, 2015 Four years since ... Queen – which coincided with the marriage of Avasa & Matthew ... THE ROAD, which is scheduled for release through White Swan Records ... message that there is a sacred path available to all of ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... released a new blog post explaining the importance of keeping a ... of an auto insurance policy . , Clients who driver ... their vehicle insurance policies. The safety a vehicle offers from its ... of this, drivers should always carry a first aid kit in ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... to announce TRIZCON2008, a conference that focuses on the ... anniversary, the largest international TRIZ conference in the world ... Universitys Student Center in Kent, Ohio, from April 13-15, ... new and experienced users to get an in-depth introduction ...
... 19 With sales forces shrinking,across the pharmaceutical ... rep time, winning a place on hospital formularies ... companies are relying on,specialized training classes to help ... hospital environment, according to recent,research from pharmaceutical benchmarking ...
... Robin Nasatir,has been promoted to President/Chief Operating Officer ... valued team of project,leaders who help organizations improve ... with the firm,s celebration of 35,years in business ... and operated enterprise., "Robin and I have ...
... NEW YORK (Feb. 19, 2008) -- A longstanding puzzle in ... team led by scientists at Weill Cornell Medical College says ... the developing neuron,s long, skinny axon affect gene transcription back ... the first-ever evidence of a transcription factor -- proteins that ...
... In response to recent media,reports, Roche would like to ... antiviral medication for the 2007-2008,flu season, and that physicians ... if flu strikes., Some news reports have indicated ... measures in place to ensure that Tamiflu is readily,available. ...
... controls the production and activation of granulocytes, white ... pathogens. , Relevance: This is the first microRNA ... innate immune response. Absence of microRNA-223 increased the ... inflammation and damage. Increased production of microRNA-223 may ...
Cached Medicine News:Health News:TRIZCON2008 at Kent State, April 13-15 2Health News:Building an Effective Sales Force to Serve the U.S. Hospital Market 2Health News:Cliff Consulting, Inc. Transitions to Woman-Owned and Managed Firm With Robin Nasatir's Promotion to President/Chief Operating Officer 2Health News:Scientists shed light on long-distance signaling in developing neurons 2Health News:Scientists shed light on long-distance signaling in developing neurons 3Health News:Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide 2Health News:Single microRNA fine-tunes innate immune response 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: